Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

NCT05564884 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2022-10-04

No results posted yet for this study

Summary

To assess the association between neonatal SARS-CoV-2 antibody level at delivery and infant COVID-19 infection under age 6 months, and to identify predictive factors for neonatal antibody level at delivery.

Conditions

Interventions

OTHER

no intervantion

no intervention

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Liat Ashkenazi-Hoffnung · Schneider children medical center

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-12
Primary Completion
2022-02-24
Completion
2022-11-01

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05564884 on ClinicalTrials.gov